secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocean Biomedical, Inc. (OCEA)
CIK:        0001869974
Form:       8-K
Filed at:   2023-02-09T23:59:59+00:00
Accession:  0001493152-23-004004
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocean Biomedical awarded multiple patents for CHI3L1 antibody cancer therapies; deal with Aesther SPAC pending
--------------------------------------------------------------------------------

- Dr. Jack A. Elias granted patents for mono-specific and bispecific antibodies targeting CHI3L1 to suppress multiple cancers.
- Antibodies cover CHI3L1 alone, CHI3L1/PD-1 bispecific, and CHI3L1/CTLA4 bispecific.
- Technology described as 'master regulator' of immune checkpoint pathways; shown to control lung cancer in murine models.
- Ocean Biomedical expected to list on Nasdaq under OCEA/OCEAW after business combination with Aesther (AEHA).
- Patents cover prostate, colon, ovarian, breast, lung cancers, glioblastoma, melanoma, etc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869974/000149315223004004/0001493152-23-004004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869974/000149315223004004/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-004004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer